TY - JOUR
T1 - Combination testing of cediranib (AZD2171) against childhood cancer models by the pediatric preclinical testing program
AU - Morton, Christopher L.
AU - Maris, John M.
AU - Keir, Stephen T.
AU - Gorlick, Richard
AU - Kolb, E. Anders
AU - Billups, Catherine A.
AU - Wu, Jianrong
AU - Smith, Malcolm A.
AU - Houghton, Peter J.
PY - 2012/4
Y1 - 2012/4
N2 - Background: Cediranib (AZD2171) is a potent small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors. Cediranib has demonstrated single agent activity in several adult cancers and is being studied in combination with standard cytotoxic agents in multiple disease settings. Procedures: Cediranib was tested in vivo against six childhood tumor xenograft models (four sarcomas, one glioblastoma, one neuroblastoma) alone or combined with cyclophosphamide (two models), vincristine (three models) or cisplatin (one model), each administered at its maximum tolerated dose, or rapamycin (six models). Results: The combination of cediranib with standard cytotoxic agents was superior to the cytotoxic agent used alone for a single xenograft (one of the three xenografts evaluated for the vincristine-cediranib combination). The cediranib-cyclophosphamide combination was inferior to single agent cyclophosphamide in time to event for both models studied and was significantly inferior for one of the models. Cediranib combined with rapamycin was superior to each of the agents used alone in two of the six models and was determined to be additive or supra-additive with rapamycin in four models, although the effects were not large. Conclusions: Cediranib combined with cytotoxic chemotherapy agents demonstrated little or no benefit (and in one case was significantly inferior) compared to chemotherapy alone for the six pediatric cancer xenografts studied. By contrast, the combination of cediranib with rapamycin was additive or supra-additive in four of the six models in terms of prolongation of time to event, though tumor regressions were not observed for this combination.
AB - Background: Cediranib (AZD2171) is a potent small molecule inhibitor of vascular endothelial growth factor (VEGF) receptors. Cediranib has demonstrated single agent activity in several adult cancers and is being studied in combination with standard cytotoxic agents in multiple disease settings. Procedures: Cediranib was tested in vivo against six childhood tumor xenograft models (four sarcomas, one glioblastoma, one neuroblastoma) alone or combined with cyclophosphamide (two models), vincristine (three models) or cisplatin (one model), each administered at its maximum tolerated dose, or rapamycin (six models). Results: The combination of cediranib with standard cytotoxic agents was superior to the cytotoxic agent used alone for a single xenograft (one of the three xenografts evaluated for the vincristine-cediranib combination). The cediranib-cyclophosphamide combination was inferior to single agent cyclophosphamide in time to event for both models studied and was significantly inferior for one of the models. Cediranib combined with rapamycin was superior to each of the agents used alone in two of the six models and was determined to be additive or supra-additive with rapamycin in four models, although the effects were not large. Conclusions: Cediranib combined with cytotoxic chemotherapy agents demonstrated little or no benefit (and in one case was significantly inferior) compared to chemotherapy alone for the six pediatric cancer xenografts studied. By contrast, the combination of cediranib with rapamycin was additive or supra-additive in four of the six models in terms of prolongation of time to event, though tumor regressions were not observed for this combination.
KW - AZD2171
KW - Cediranib
KW - Developmental therapeutics
KW - Preclinical testing
UR - http://www.scopus.com/inward/record.url?scp=84863116086&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863116086&partnerID=8YFLogxK
U2 - 10.1002/pbc.23159
DO - 10.1002/pbc.23159
M3 - Article
C2 - 21538824
AN - SCOPUS:84863116086
SN - 1545-5009
VL - 58
SP - 566
EP - 571
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - 4
ER -